


CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

22-509

RISK ASSESSMENT and RISK MITIGATION REVIEW(S)



**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology**

Date: January 28, 2010

To: Russell Katz, MD, Director
Division of Neurology Products (DNP)

Through: Claudia Karwoski, PharmD., Deputy Director
Division of Risk Management (DRISK)

From: Mary Dempsey, BS, Coordinator
Risk Management Programs, DRISK

LaShawn Griffiths, MSHS-PH, BSN, RN
Acting Team Leader, Patient Labeling Reviewer

Subject: Review Proposed REMS Amendment NDA 022509;
Proposed Risk Evaluation and Mitigation Strategy (REMS)
REMS Modification; REMS Assessment

Drug Name(s): Lamictal (lamotrigine) XR

Application Type/Number: NDA: 022509

Applicant/sponsor: SmithKline Beecham d/b/a GlaxoSmithKline

OSE RCM #: 2009-2276

1. Background

Lamictal Tablets, Orally Disintegrating Tablets (ODT) and Lamictal Chewable Dispersible Tablets Medication Guide (MG)-only REMS was approved May 8, 2009. Lamictal XR (Extended Release Tablets) Medication Guide (MG) REMS was approved May 29, 2009. At that time all Lamictal products shared the same REMS. In a January 15, 2010 teleconference, the Division of Neurology Products (DNP) notified the sponsor that because Lamictal XR (lamotrigine) and the other Lamictal formulations do not share the same Medication Guide, they may not be included in the same REMS. On January 26,

2010 DRISK received a request from the DNP to review the proposed REMS modification submitted January 18, 2010. This proposed REMS Modification contains a revised Medication Guide to include the new indication and the removal of the other Lamictal formulations from the REMS document.

2. Material Reviewed

- May 29, 2009 Lamictal XR REMS approval including Medication Guide
- December 15, 2009 response to November 30, 2009 Complete Response (CR)
- January 18, 2010 proposed REMS Modification including Medication Guide and REMS Assessment

3. Proposed REMS Elements

The cover letter of the January 18, 2010 submission which provides the REMS Modification, REMS Assessment and Medication Guide states the following:

“As requested, reference to the other approved formulations of LAMICTAL (Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets) have been removed, thus making a separate REMS for LAMICTAL XR. In addition, the assessment to evaluate distribution of the Medication Guide was removed because all presentations of LAMICTAL XR are unit-of-use. No safety information was added or revised.

It is too early to assess the REMS at this time. The Medication Guide would be adequate with the proposed modifications to achieve its purpose.”

4. Conclusion

DRISK performed an electronic comparison of the January 18, 2010 submitted REMS and Medication Guide and found the document to be identical to the approved REMS and Medication Guide with the exception of the revised Medication Guide to include the new indication, and the removal of the other Lamictal formulations from the REMS document; no safety information was added or revised. This constitutes a separate Medication Guide REMS for Lamictal XR.

DRISK agrees that the Sponsor’s proposed REMS Modification for Lamictal XR meets the statutory requirements in accordance with section 505-1 of FDCA, as one element of a REMS, FDA may require the development of a Medication Guide as provided for under 21 CFR Part 208.

5. Recommendation

Acceptable

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22509	ORIG-1	SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLIN E	LAMICTAL XR(LAMOTRIGINE)ORAL TABLETS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY J DEMPSEY
01/28/2010

CLAUDIA B KARWOSKI
01/29/2010
concur